title: First-in-class angiotensin receptor neprilysin inhibitor in heart failure.
abstract: Neprilysin inhibitors augment the natriuretic peptide system by preventing the breakdown of atrial natriuretic peptide and B-type natriuretic peptide. LCZ696, an angiotensin receptor neprilysin inhibitor composed of a neprilysin inhibitor prodrug and the angiotensin receptor antagonist valsartan, has proven effective in hypertension, has shown promise in a pilot trial of heart failure with preserved ejection fraction, and is being tested in a large outcomes trial of heart failure with reduced ejection fraction. A preserved ejection fraction outcomes trial is beginning.
authors.affiliation: School of Pharmacy, University of Wisconsin, Madison, Wisconsin, USA.
authors.forename: O
authors.initials: O
authors.lastname: Vardeny
authors.forename: T
authors.initials: T
authors.lastname: Tacheny
authors.forename: S D
authors.initials: SD
authors.lastname: Solomon
mesh_terms: D000613:Aminobutyrates / Q000627:therapeutic use*; D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D004338:Drug Combinations; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008954:Models, Biological; D015260:Neprilysin / Q000037:antagonists & inhibitors*; D013318:Stroke Volume / Q000187:drug effects / Q000502:physiology; D013777:Tetrazoles / Q000627:therapeutic use*; D000068756:Valsartan
chemical_list: D000613:Aminobutyrates; D057911:Angiotensin Receptor Antagonists; D001713:Biphenyl Compounds; D004338:Drug Combinations; D013777:Tetrazoles; D000068756:Valsartan; D015260:Neprilysin; C549068:sacubitril and valsartan sodium hydrate drug combination